SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-030624
Filing Date
2024-04-05
Accepted
2024-04-05 08:30:17
Documents
18
Period of Report
2024-04-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea020336201-8k_allarity.htm   iXBRL 8-K 25888
2 PRESS RELEASE, DATED APRIL 4, 2024 ea020336201ex99-1_allarity.htm EX-99.1 18609
3 GRAPHIC image_001.jpg GRAPHIC 3027
4 GRAPHIC image_004.jpg GRAPHIC 3027
5 GRAPHIC image_003.jpg GRAPHIC 3027
6 GRAPHIC image_002.jpg GRAPHIC 3027
  Complete submission text file 0001213900-24-030624.txt   242562

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE allr-20240404.xsd EX-101.SCH 3015
8 XBRL LABEL FILE allr-20240404_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE allr-20240404_pre.xml EX-101.PRE 22359
21 EXTRACTED XBRL INSTANCE DOCUMENT ea020336201-8k_allarity_htm.xml XML 3731
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 24824828
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)